Twenty Twenty Therapeutics

Twenty Twenty Therapeutics is focused on harnessing the convergence of AI, microelectronics and scalable digital technologies with diagnostic and preventative eye care to bring innovative solutions for eye diseases to market. The company's vision is to eliminate preventable blindness. By transforming the delivery of today's eye-care, the company is... improving patient access to intuitive and affordable diagnostics and treatments. The company believes it should be easy for doctors to deliver superior outcomes to their patients. The company's technology empowers patients to care for their own vision in between doctors visits. To accomplish these goals, the company develops, market and commercialize transformative innovations in diagnostics, sensing, and preventative / medical / surgical treatments for eye diseases. The company were formed in August 2020 as a joint venture between Verily Life Sciences, an Alphabet company, and Santen, a leading Japanese pharmaceutical company. The company is passionate and committed to building and sustaining an inclusive and equitable working environment. Every member on the company's team enriches the company's diversity by exposing the company to a broad range of views that help the company understand and engage with the world, identify challenges, and to discover, design and deliver solutions. The Twenty Twenty work environment empowers the company's team to do their absolute best work.Read More